Trial · NCT01276509
Results by group135
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 135
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 22.5 mg | Week 8 (n =50, 55, 62, 56) | 52.7 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 75 mg | Week 8 (n =50, 55, 62, 56) | 60.1 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 225 mg | Week 8 (n =50, 55, 62, 56) | 62.7 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | Placebo | Week 8 (n =50, 55, 62, 56) | 47.7 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 22.5 mg | Week 12 (n = 51, 49, 61, 54) | 62.0 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 75 mg | Week 12 (n = 51, 49, 61, 54) | 64.7 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | PF-00547659 225 mg | Week 12 (n = 51, 49, 61, 54) | 57.5 | Percentage of Participants | |
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate | Placebo | Week 12 (n = 51, 49, 61, 54) | 58.6 | Percentage of Participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 22.5 mg | Participants with AEs (all causalities) | 57 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 75 mg | Participants with AEs (all causalities) | 51 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 225 mg | Participants with AEs (all causalities) | 54 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | Placebo | Participants with AEs (all causalities) | 54 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 22.5 mg | Participants with AEs (treatment related) | 20 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 75 mg | Participants with AEs (treatment related) | 24 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 225 mg | Participants with AEs (treatment related) | 29 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | Placebo | Participants with AEs (treatment related) | 22 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 22.5 mg | Withdrawal due to AEs (all causalities) | 9 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 75 mg | Withdrawal due to AEs (all causalities) | 8 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | PF-00547659 225 mg | Withdrawal due to AEs (all causalities) | 4 | Number of participants | |
| Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo | Placebo | Withdrawal due to AEs (all causalities) | 3 | Number of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01276509/results